Omicron variant: BioNTech, Moderna expect data on vaccine protection soon

- Advertisement -

BioNTech SE said on Friday it expects more data about a worrying new coronavirus variant in South Africa within two weeks to help determine whether its vaccine produced with partner Pfizer Inc. Gotta work.

- Advertisement -

Pfizer and BioNTech said they expect to be able to ship a new vaccine compliant with the emerging version in about 100 days, if needed.

“We understand the concern of the experts and have immediately started testing the variant B.1.1.529,” BioNTech said in a statement.


“We expect more data from laboratory tests in the latest two weeks. These data will provide further information about whether B. may be an escaped variant that may require adjustments to our vaccine if the variant spreads globally,” it added.

Story continues below ad

- Advertisement -

Moderna Inc. said in a statement that it is working to advance a booster candidate compliant with the new version and is testing higher doses of its existing boosters and other boosters designed to protect against multiple types. Studying candidates.

“The booster dose of an authorized vaccine represents the only strategy currently available to enhance weakened immunity,” Moderna said in the statement.

Escape variants are those that avoid the targeted immune response brought on by vaccination. BioNTech said Pfizer and BioNTech will be able to redesign their shot within six weeks and ship initial batches within 100 days.

On Friday, BioNTech ADRs were up 14.2 percent at $348 and Pfizer shares were up 6.1 percent at $54. Moderna closed at $329.63, up 20.6 per cent.

Granthshala officials reacted with alarm to the new version on Friday, with the European Union and Britain tightening border controls amid scientists trying to find out whether the mutation was vaccine-resistant.

Story continues below ad

Pfizer and BioNTech have already created versions of their established mRNA-based vaccine – based on the original virus found in the Chinese city of Wuhan – to target so-called alpha and delta variants, in clinical trials. are continuing.

Those efforts are not to obtain a commercial product; This exercise is done with regulators to establish a routine that will help speed up any future vaccine relaunches.

Analysts at Evercore ISI said data from another recent edition in Qatar showed a high level of initial efficacy by current vaccines that faded significantly after four months of dosing.

Johnson & Johnson said it is also closely monitoring emerging strains of COVID-19 and testing the effectiveness of its shot against the new variant.

View Link »

- Advertisement -
Mail Us For  DMCA / Credit  Notice

Recent Articles

Stay on top - Get the daily news in your inbox

Related Stories